Clean Yield Group Increases Stake in Hologic, Inc. $HOLX

Key Points

• Clean Yield Group has increased its stake in Hologic, Inc. by 10.5% during the second quarter, bringing its total shares to 58,462, valued at approximately $3.8 million.
• Hologic reported a quarterly earnings per share of $1.08, surpassing analysts' expectations and experiencing a 1.2% year-over-year revenue increase.
• Institutional investors collectively hold 94.73% of Hologic's stock, indicating significant confidence from large investors in the company's future performance.

Clean Yield Group increased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 10.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,462 shares of the medical equipment provider's stock after buying an additional 5,553 shares during the period. Clean Yield Group's holdings in Hologic were worth $3,809,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Victory Capital Management Inc. increased its stake in shares of Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after buying an additional 1,692,177 shares during the period. Invesco Ltd. increased its stake in shares of Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after buying an additional 764,573 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Hologic by 1.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock valued at $276,303,000 after buying an additional 69,878 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Hologic by 0.8% during the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock valued at $216,973,000 after buying an additional 29,133 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Hologic by 8.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider's stock valued at $175,331,000 after buying an additional 213,366 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $67.21 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company has a market cap of $14.95 billion, a PE ratio of 27.89, a P/E/G ratio of 2.44 and a beta of 0.57. The business has a 50-day simple moving average of $66.76 and a two-hundred day simple moving average of $62.89. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.88% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on HOLX shares. Argus lifted their target price on Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research note on Friday, September 19th. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and lifted their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Evercore ISI lifted their target price on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. UBS Group lifted their target price on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. Finally, Mizuho set a $75.00 target price on Hologic in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Hologic currently has an average rating of "Moderate Buy" and an average price target of $79.38.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.